A targeted salvage therapy with Brentuximab vedotin in heavily treated refractory or relapsed pediatric Hodgkin lymphoma patients before and after stem cell transplantation
TURKISH JOURNAL OF PEDIATRICS, cilt.61, sa.5, ss.671-676, 2019 (SCI-Expanded, Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 61 Sayı: 5
- Basım Tarihi: 2019
- Doi Numarası: 10.24953/turkjped.2019.05.005
- Dergi Adı: TURKISH JOURNAL OF PEDIATRICS
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.671-676
- Anahtar Kelimeler: Hodgkin lymphoma, brentuximab vedotin, EXPERIENCE, RISK, MULTICENTER, PROGRAM, SGN-35, CD30
- İstanbul Üniversitesi Adresli: Hayır
Özet
Hodgkin's lymphoma (HL) is highly curable disease in its early stages, but in advanced stages, it presents a dilemma when it becomes refractory or relapses after several rounds of chemotherapy. Brentuximab vedotin (BV) is an antibody-drug conjugate that targets the tumor necrosis receptor family protein member CD30 positive malignancies via an anti-CD30 monoclonal antibody linked to monomethyl auristatin-E. In adult and pediatric studies, it has been shown to be an effective salvage therapy for primary refractory HL or relapse after autologous stem cell transplant (ASCT).